FRANKLIN LAKES, N.J.--(BUSINESS WIRE)--April 28, 2006--ReGen Biologics, Inc. (OTC: RGBI - News) provided an update today indicating that it is responding to a request for additional information from the FDA with respect to its 510(k) submission for its collagen scaffold device. “We submitted the 510(k) on December 28, 2005 and our guidance relating to the 510(k) indicated that we expected a timeline of six to nine months before a decision from the FDA,” stated Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics. “We are currently responding to a request for additional information from the FDA and our timeline guidance has not changed.”
